Woodley Farra Manion Portfolio Management Continues to Hold Holding in Novartis (NVS); As Pfizer (PFE) Market Value Declined, Holder Cypress Capital Group Has Cut Its Stake by $544,075

February 24, 2018 - By Kurt Siggers

Woodley Farra Manion Portfolio Management Inc increased its stake in Novartis (NVS) by 1.56% based on its latest 2017Q3 regulatory filing with the SEC. Woodley Farra Manion Portfolio Management Inc bought 5,373 shares as the company’s stock rose 4.17% with the market. The institutional investor held 348,982 shares of the major pharmaceuticals company at the end of 2017Q3, valued at $29.96 million, up from 343,609 at the end of the previous reported quarter. Woodley Farra Manion Portfolio Management Inc who had been investing in Novartis for a number of months, seems to be bullish on the $199.20 billion market cap company. The stock increased 0.15% or $0.13 during the last trading session, reaching $85.33. About 1.13M shares traded. Novartis AG (NYSE:NVS) has risen 7.67% since February 24, 2017 and is uptrending. It has underperformed by 9.03% the S&P500.

Cypress Capital Group decreased its stake in Pfizer Inc (PFE) by 13.6% based on its latest 2017Q3 regulatory filing with the SEC. Cypress Capital Group sold 15,545 shares as the company’s stock declined 3.45% while stock markets rallied. The institutional investor held 98,779 shares of the health care company at the end of 2017Q3, valued at $3.53 million, down from 114,324 at the end of the previous reported quarter. Cypress Capital Group who had been investing in Pfizer Inc for a number of months, seems to be less bullish one the $216.14B market cap company. The stock increased 1.45% or $0.52 during the last trading session, reaching $36.26. About 17.02 million shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since February 24, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

Among 16 analysts covering Novartis Ag (NYSE:NVS), 5 have Buy rating, 4 Sell and 7 Hold. Therefore 31% are positive. Novartis Ag had 36 analyst reports since July 28, 2015 according to SRatingsIntel. The rating was downgraded by Mainfirst to “Underperform” on Wednesday, October 28. JP Morgan maintained Novartis AG (NYSE:NVS) on Wednesday, April 19 with “Neutral” rating. The stock has “Neutral” rating by UBS on Friday, April 1. The stock has “Overweight” rating by Morgan Stanley on Wednesday, July 26. Leerink Swann maintained the stock with “Market Perform” rating in Monday, October 23 report. The firm earned “Neutral” rating on Tuesday, January 3 by JP Morgan. The firm has “Neutral” rating by J P Morgan Chase Co given on Friday, June 16. The firm earned “Neutral” rating on Thursday, March 23 by Goldman Sachs. The stock of Novartis AG (NYSE:NVS) earned “Neutral” rating by Citigroup on Tuesday, March 29. The firm has “Hold” rating given on Tuesday, April 5 by Argus Research.

Woodley Farra Manion Portfolio Management Inc, which manages about $607.27 million and $863.12 million US Long portfolio, decreased its stake in Chevron (NYSE:CVX) by 17,390 shares to 172,349 shares, valued at $20.25M in 2017Q3, according to the filing. It also reduced its holding in Enterprise Products Partners (NYSE:EPD) by 27,580 shares in the quarter, leaving it with 36,758 shares, and cut its stake in Microsoft (NASDAQ:MSFT).

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on May, 1. They expect $0.70 earnings per share, up 1.45% or $0.01 from last year’s $0.69 per share. PFE’s profit will be $4.17B for 12.95 P/E if the $0.70 EPS becomes a reality. After $0.62 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts 12.90% EPS growth.

Cypress Capital Group, which manages about $45.36M and $469.34 million US Long portfolio, upped its stake in Jpmorgan Chase & Co (NYSE:JPM) by 8,005 shares to 84,220 shares, valued at $8.04 million in 2017Q3, according to the filing. It also increased its holding in Church & Dwight Co Inc (NYSE:CHD) by 8,489 shares in the quarter, for a total of 32,453 shares, and has risen its stake in Hasbro Inc (NASDAQ:HAS).

Investors sentiment increased to 0.96 in 2017 Q3. Its up 0.02, from 0.94 in 2017Q2. It improved, as 53 investors sold PFE shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported. Moreover, Monetary Mngmt Grp has 0.39% invested in Pfizer Inc. (NYSE:PFE). Savant Limited Liability Company holds 52,641 shares or 0.42% of its portfolio. Coastline Tru Com invested 0.72% of its portfolio in Pfizer Inc. (NYSE:PFE). Webster Financial Bank N A has 0.89% invested in Pfizer Inc. (NYSE:PFE). Argi Investment Svcs Lc invested 0.12% of its portfolio in Pfizer Inc. (NYSE:PFE). Bkd Wealth Advsr Lc accumulated 0.39% or 100,213 shares. Moreover, Gulf International Bankshares (Uk) has 0.91% invested in Pfizer Inc. (NYSE:PFE) for 1.89M shares. Alliancebernstein Limited Partnership has 0.53% invested in Pfizer Inc. (NYSE:PFE). Hgk Asset Management Inc, a New Jersey-based fund reported 422,536 shares. Concorde Asset Mngmt Ltd Liability Com reported 0.31% of its portfolio in Pfizer Inc. (NYSE:PFE). Voloridge Mngmt Limited Co reported 0.35% stake. Alta Mngmt Ltd Limited Liability Company holds 0.01% or 5,979 shares. Pictet Asset Mngmt has 0.49% invested in Pfizer Inc. (NYSE:PFE). Exxonmobil Tx invested in 0.98% or 1.09M shares. Fred Alger Inc invested in 0.02% or 110,057 shares.

Since August 31, 2017, it had 0 insider buys, and 7 insider sales for $12.30 million activity. MACKENZIE ALEXANDER R also sold $249,750 worth of Pfizer Inc. (NYSE:PFE) on Friday, December 15. READ IAN C had sold 197,168 shares worth $6.70M. $3.21 million worth of Pfizer Inc. (NYSE:PFE) was sold by DAMELIO FRANK A. $296,560 worth of stock was sold by JOHNSON RADY A on Friday, December 15.

Among 22 analysts covering Pfizer (NYSE:PFE), 10 have Buy rating, 1 Sell and 11 Hold. Therefore 45% are positive. Pfizer had 74 analyst reports since July 29, 2015 according to SRatingsIntel. As per Thursday, July 13, the company rating was maintained by Jefferies. The firm has “Buy” rating given on Wednesday, August 2 by Piper Jaffray. The rating was maintained by Piper Jaffray with “Overweight” on Friday, August 28. The stock of Pfizer Inc. (NYSE:PFE) earned “Buy” rating by Jefferies on Thursday, April 7. Guggenheim initiated the shares of PFE in report on Friday, December 2 with “Neutral” rating. The firm has “Hold” rating given on Monday, June 12 by BMO Capital Markets. On Saturday, September 5 the stock rating was maintained by Piper Jaffray with “Overweight”. The rating was initiated by Societe Generale on Wednesday, April 6 with “Hold”. Cowen & Co maintained the shares of PFE in report on Monday, August 14 with “Buy” rating. On Monday, July 10 the stock rating was maintained by Cowen & Co with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: